IN Brief:
- Glanbia increased first-half revenue by 7% to approximately $2.1 billion.
- Performance, health, and dairy nutrition all grew, while whey inflation continued to pressure margins.
- The group raised earnings guidance and increased its annual transformation savings target to $70 million.
Glanbia has raised its full-year earnings outlook after reporting revenue and volume growth across Performance Nutrition, Health and Nutrition, and Dairy Nutrition during the first half of 2026.
Revenue reached $2.1 billion for the six months ended 4 July, an increase of 7% on a constant-currency basis and 7.9% as reported. EBITDA before exceptional items rose by 14.1% to $275.4 million, while adjusted earnings per share increased by 30% to 81.24 US cents.
The group now expects constant-currency adjusted earnings-per-share growth of 17% to 20% for the full year, compared with previous guidance at the upper end of a 7% to 11% range. It also raised expectations for its two main growth divisions and increased the annual savings target attached to its transformation programme from $60 million to $70 million by the end of 2027.
Performance Nutrition delivered like-for-like revenue growth of 16.9%, comprising 9.3% volume growth and 7.6% pricing. Optimum Nutrition grew like-for-like revenue by 25.2%, although the division’s EBITDA margin slipped from 12.7% to 12.6% as elevated whey costs continued to affect the business.
Demand growth meets input inflation
The margin movement shows why stronger demand does not translate automatically into easier manufacturing economics. Whey proteins account for a large share of many sports and active-nutrition formulations, so higher raw-material costs can move quickly through products with high protein loading.
Manufacturers then have to recover pressure through pricing, procurement, productivity, pack architecture, and product mix without weakening brand position or customer service. Glanbia achieved both volume and pricing growth in Performance Nutrition, but the slight margin reduction indicates that the cost headwind has not disappeared.
Health and Nutrition recorded like-for-like revenue growth of 12%, driven by a 14.3% increase in volume. Its EBITDA margin fell to 18.4% from 19.5%, while the group continued capacity expansion in the US, China, and Europe.
Dairy Nutrition produced EBITDA of $92.3 million, up from $72.2 million a year earlier, supported by volume and pricing growth in protein solutions. Glanbia increased full-year EBITDA guidance for the division to between $170 million and $180 million, from $160 million to $170 million.
The figures reinforce the industrial attraction of nutrition-focused dairy processing. The recent Kinisla dairy investment programme placed similar emphasis on higher-value nutrition ingredients and processing capability. Milk and whey can be separated, concentrated, dried, and formulated for sports nutrition, healthy ageing, weight management, clinical applications, and mainstream fortification.
Those routes can create more value than commodity disposal, but they require specialist membranes, evaporation, drying, blending, analytical control, and application support.
New capacity must convert into margin
Glanbia’s upgraded outlook rests on more than sales momentum. The group is pursuing a transformation programme intended to remove $70 million of annual cost by 2027, placing procurement, manufacturing efficiency, shared services, and portfolio discipline alongside revenue growth.
Savings of that scale have to be delivered without weakening quality systems, innovation capability, or service to customers whose products rely on tightly specified ingredients. The same constraint applies to capacity expansion: additional lines can relieve bottlenecks and place production closer to customers, but they add depreciation, labour, validation, inventory, and start-up costs before utilisation reaches an efficient level.
The group’s projects in the US, China, and Europe will therefore matter as much as the headline demand figures. Strong end markets provide the opportunity, but margins will depend on commissioning discipline, product mix, and how quickly new assets reach stable output.
Nutrition ingredients also carry demanding service requirements. Customers may need different protein concentrations, flavour systems, agglomeration properties, particle sizes, or solubility profiles, while regulatory and labelling requirements vary by market. Capacity has to be flexible enough to handle those specifications without allowing short campaigns and cleaning cycles to erode the benefit of higher volumes.
Working capital will remain part of that equation. High-value ingredients, longer export routes, and capacity ramp-ups can increase inventory before sales convert to cash. Glanbia’s stronger earnings provide room to manage the transition, but the enlarged savings target leaves little tolerance for poorly utilised assets or avoidable process loss.
Glanbia ended the period with net debt at 1.41 times adjusted EBITDA, compared with 1.28 times a year earlier. It increased the interim dividend by 10% and returned €100 million through share buybacks, indicating that management expects the balance sheet to support investment, transformation, and shareholder returns together.
The second half will test whether pricing, productivity, and capacity utilisation can continue to offset whey inflation and expansion costs. By raising guidance now, Glanbia has also raised the operating standard against which the remaining six months will be judged.
